Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mpox mRNA vaccine (Afrigen Biologics)
- Development stage
- Preclinical
- Lead developer
- Afrigen Biologics and Vaccines
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, mRNA Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The Mpox mRNA vaccine is an investigational vaccine candidate being developed by Afrigen Biologics. It is one of the flagship programs within the WHO-supported mRNA technology transfer hub initiative, which aims to build vaccine manufacturing capacity in low- and middle-income countries. The vaccine utilizes messenger RNA (mRNA) technology to encode specific antigens from the Mpox virus (an orthopoxvirus). Upon administration, the mRNA instructs host cells to produce these viral antigens, which then stimulate the immune system to generate protective antibodies and T-cell responses against the virus. This program is part of a broader effort to address global health security and ensure equitable access to vaccines for emerging infectious diseases.
- Other names
- Afrigen Mpox mRNA vaccinemRNA-Mpox (Afrigen)
02
Targets
OPXV MV/EEV antigens (Orthopoxvirus mature virion and extracellular enveloped virion surface antigens)
Beyond the preview
Go deeper on Mpox mRNA vaccine (Afrigen Biologics).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Mpox mRNA vaccine (Afrigen Biologics).